BAY 94-9172 PET/CT in Cognitively Normal Older Adults, Older Adults With Mild Cognitive Impairment, and Older Adults With Alzheimer's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 May 2018
Price : $35 *
At a glance
- Drugs Florbetaben F18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- 31 Aug 2018 Biomarkers information updated
- 21 May 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2029.
- 21 May 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.